DE69434115D1 - Inhibitor des wachstumsfaktors für gefäss-endothelzellen - Google Patents

Inhibitor des wachstumsfaktors für gefäss-endothelzellen

Info

Publication number
DE69434115D1
DE69434115D1 DE69434115T DE69434115T DE69434115D1 DE 69434115 D1 DE69434115 D1 DE 69434115D1 DE 69434115 T DE69434115 T DE 69434115T DE 69434115 T DE69434115 T DE 69434115T DE 69434115 D1 DE69434115 D1 DE 69434115D1
Authority
DE
Germany
Prior art keywords
growth factor
inhibitor
vessel
vegf
soluble forms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69434115T
Other languages
English (en)
Other versions
DE69434115T2 (de
Inventor
Richard L Kendall
Kenneth A Thomas Jr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Application granted granted Critical
Publication of DE69434115D1 publication Critical patent/DE69434115D1/de
Publication of DE69434115T2 publication Critical patent/DE69434115T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE69434115T 1993-03-25 1994-02-25 Inhibitor des wachstumsfaktors für gefässendothelzellen Expired - Fee Related DE69434115T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3876993A 1993-03-25 1993-03-25
US38769 1993-03-25
PCT/US1994/001957 WO1994021679A1 (en) 1993-03-25 1994-02-25 Inhibitor of vascular endothelial cell growth factor

Publications (2)

Publication Number Publication Date
DE69434115D1 true DE69434115D1 (de) 2004-12-09
DE69434115T2 DE69434115T2 (de) 2005-10-27

Family

ID=21901791

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69434115T Expired - Fee Related DE69434115T2 (de) 1993-03-25 1994-02-25 Inhibitor des wachstumsfaktors für gefässendothelzellen

Country Status (12)

Country Link
US (5) US5712380A (de)
EP (1) EP0694042B1 (de)
JP (1) JP3734262B2 (de)
AT (1) ATE281469T1 (de)
AU (1) AU684498B2 (de)
CA (1) CA2158745C (de)
DE (1) DE69434115T2 (de)
DK (1) DK0694042T3 (de)
ES (1) ES2230542T3 (de)
IL (1) IL109016A (de)
PT (1) PT694042E (de)
WO (1) WO1994021679A1 (de)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6710174B2 (en) * 2001-09-13 2004-03-23 Isis Pharmaceuticals, Inc. Antisense inhibition of vascular endothelial growth factor receptor-1 expression
GB9410533D0 (en) * 1994-05-26 1994-07-13 Lynxvale Ltd In situ hybridisation and immuno-Chemical localisation of a growth factor
GB9410534D0 (en) * 1994-05-26 1994-07-13 Lynxvale Ltd Improvements in or relating to growth factor inhibitors
JPH09154588A (ja) 1995-10-07 1997-06-17 Toagosei Co Ltd Ｖｅｇｆ結合性ポリペプチド
US6346398B1 (en) 1995-10-26 2002-02-12 Ribozyme Pharmaceuticals, Inc. Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
US7034009B2 (en) 1995-10-26 2006-04-25 Sirna Therapeutics, Inc. Enzymatic nucleic acid-mediated treatment of ocular diseases or conditions related to levels of vascular endothelial growth factor receptor (VEGF-R)
GB9601640D0 (en) * 1996-01-26 1996-03-27 Cancer Res Campaign Tech Ligand directed enzyme prodrug therapy
US6100071A (en) * 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
WO1998002543A1 (fr) 1996-07-15 1998-01-22 Chugai Research Institute For Molecular Medicine, Inc. Nouveaux facteurs analogues au vegf
CA2266419A1 (en) * 1996-09-24 1998-04-02 Merck & Co., Inc. Gene therapy for inhibition of angiogenesis
US6750044B1 (en) 1996-10-17 2004-06-15 Genentech, Inc. Variants of vascular endothelial cell growth factor having antagonistic properties, nucleic acids encoding the same and host cells comprising those nucleic acids
WO1998031794A1 (fr) 1997-01-17 1998-07-23 Toa Gosei Co., Ltd. Polypeptide liant le facteur vegf
AU3850299A (en) * 1998-05-20 1999-12-06 Kyowa Hakko Kogyo Co. Ltd. Vegf activity inhibitors
US7317003B2 (en) * 1998-09-04 2008-01-08 National University Of Singapore Small peptides having anti-angiogenic and endothelial cell inhibition activity
US6200954B1 (en) * 1998-09-04 2001-03-13 National University Of Singapore Small peptides having potent anti-angiogenic activity
US6696063B1 (en) * 1998-12-30 2004-02-24 Applied Research Systems Ars Holding N.V. Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy
ATE348629T1 (de) * 1999-01-15 2007-01-15 Medstar Res Inst Behandlung von restenose und atherosklerose mit einem löslichen vegf rezeptor und angiopoietin-1
US7303746B2 (en) * 1999-06-08 2007-12-04 Regeneron Pharmaceuticals, Inc. Methods of treating eye disorders with modified chimeric polypeptides
US6833349B2 (en) * 1999-06-08 2004-12-21 Regeneron Pharmaceuticals, Inc. Methods of treating inflammatory skin diseases
US7070959B1 (en) * 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
GB9928950D0 (en) * 1999-12-07 2000-02-02 Metris Therapeutics Limited Binding protein
AU2001237256A1 (en) * 2000-03-08 2001-09-17 Neurosearch A/S A method of sensitising endothelial cells to prodrugs
ATE466069T1 (de) 2000-09-05 2010-05-15 Biosight Ltd Peptid-konjugierte antikrebs-prodrugs
US6734017B2 (en) 2001-09-28 2004-05-11 Isis Pharmaceuticals, Inc. Antisense modulation of vascular endothelial growth factor receptor-2 expression
AU2003215163A1 (en) * 2002-02-12 2003-09-04 Vanderbilt University Inhibition of vegf receptor signaling reverses tumor resistance to radiotherapy
US20040101478A1 (en) * 2002-03-29 2004-05-27 Thomas Kenneth A In vivo methods of determining activity of receptor-type kinase inhibitors
CU23178A1 (es) * 2002-04-15 2006-09-22 Ct Ingenieria Genetica Biotech INMUNOTERAPIA ACTIVA ANTIANGIOGéNICA
DK1548032T3 (da) 2002-09-12 2009-08-17 Oncotherapy Science Inc KDR-peptider og vacciner indeholdende disse
US7432341B2 (en) * 2002-10-24 2008-10-07 Valo Hsj, Limited Partnership Cytokine receptor modulators and method of modulating cytokine receptor activity
WO2004103159A2 (en) * 2003-05-14 2004-12-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for modulating endometrium
US20050239088A1 (en) * 2003-05-16 2005-10-27 Shepard H M Intron fusion proteins, and methods of identifying and using same
US7186699B2 (en) * 2003-06-03 2007-03-06 Cell Genesys, Inc. Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes
US20090155266A1 (en) * 2004-01-16 2009-06-18 Yale University Methods and Compositions Relating to Vascular Endothelial Growth Factor and TH2 Mediated Inflammatory Diseases
US8618054B2 (en) * 2004-05-05 2013-12-31 Valorisation-Rechereche Société en Commandite Interleukin-1 receptor antagonists, compositions, and methods of treatment
AU2005245896A1 (en) * 2004-05-14 2005-12-01 Receptor Biologix, Inc. Cell surface receptor isoforms and methods of identifying and using the same
EP1767546B1 (de) * 2004-06-08 2012-03-07 Chengdu Kanghong Biotechnologies Co., Ltd. Ein die angiogenese inhibierendes chimäres protein und dessen verwendung
US20080171033A1 (en) * 2004-08-26 2008-07-17 Chiwen Chang Compositions and methods for treating diseases associated with angiogenesis and inflammation
CN101094688B (zh) 2004-09-13 2013-05-01 建新公司 多聚构建体
US8841259B2 (en) * 2005-02-24 2014-09-23 Joslin Diabetes Center Compositions and methods for treating vascular permeability
WO2006093030A1 (en) * 2005-02-28 2006-09-08 Oncotherapy Science, Inc. Epitope peptides derived from vascular endothelial growth factor receptor 1 and vaccines containing these peptides
US20060234347A1 (en) * 2005-04-13 2006-10-19 Harding Thomas C Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors
US20090170769A1 (en) * 2005-05-13 2009-07-02 Pei Jin Cell surface receptor isoforms and methods of identifying and using the same
AU2006267097A1 (en) * 2005-07-13 2007-01-18 Beth Israel Deaconess Medical Center Methods of diagnosing and treating an inflammatory response
US9198981B2 (en) * 2006-02-01 2015-12-01 The University Of Kentucky Modulation of angiogenesis
WO2008091692A2 (en) * 2007-01-25 2008-07-31 Joslin Diabetes Center, Inc. Methods of diagnosing, treating, and preventing increased vascular permeability
TWI436775B (zh) 2007-08-24 2014-05-11 Oncotherapy Science Inc 以抗原胜肽合併化療藥劑治療胰臟癌
CA2711071A1 (en) * 2008-01-07 2009-07-16 Ortho-Clinical Diagnostics, Inc. Determination of sflt-1:angiogenic factor complex
WO2009149205A2 (en) * 2008-06-03 2009-12-10 Neurotech Usa, Inc. Cell lines that secrete soluble vegf receptors and uses thereof
JP2012517434A (ja) 2009-02-06 2012-08-02 ザ ジェネラル ホスピタル コーポレイション 血管病変を治療する方法
WO2010108503A1 (en) 2009-03-24 2010-09-30 Life & Brain Gmbh Promotion of neuronal integration in neural stem cell grafts
TW201109029A (en) 2009-06-11 2011-03-16 Oncotherapy Science Inc Vaccine therapy for choroidal neovascularization
ES2354922B1 (es) 2009-09-02 2012-02-07 Fundacion Institut De Recerca De L'hospital Universitari Vall D'hebron Marcadores para la selección de terapias personalizadas para el tratamiento del c�?ncer.
WO2011028642A1 (en) 2009-09-04 2011-03-10 University Of Louisville Research Foundation, Inc. Genetic determinants of prostate cancer risk
WO2012019128A1 (en) 2010-08-06 2012-02-09 Genzyme Corporation Vegf antagonist compositions and uses thereof
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
TWI775096B (zh) * 2012-05-15 2022-08-21 澳大利亞商艾佛蘭屈澳洲私營有限公司 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd)
US9770426B2 (en) 2013-01-11 2017-09-26 Massachusetts Eye And Ear Infirmary CYP450 lipid metabolites reduce inflammation and angiogenesis
EP2994758B1 (de) 2013-05-08 2017-12-20 Opthea Limited Biomarker für altersbedingte makuladegeneration (amd)
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
SG10201810150UA (en) 2014-03-17 2018-12-28 Adverum Biotechnologies Inc Compositions and methods for enhanced gene expression in cone cells
WO2015140638A1 (en) 2014-03-18 2015-09-24 Korea Advanced Institute Of Science And Technology (Kaist) Glycosylated vegf decoy receptor fusion protein
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
MA40354A (fr) 2014-07-18 2017-05-24 Sanofi Sa Procédé permettant de prédire le résultat d'un traitement avec de l'aflibercept d'un patient suspecté de souffrir d'un cancer
WO2016141078A1 (en) 2015-03-02 2016-09-09 Avalanche Biotechnologies, Inc. Compositions and methods for intravitreal delivery of polynucleotides to retinal cones
GB2545763A (en) 2015-12-23 2017-06-28 Adverum Biotechnologies Inc Mutant viral capsid libraries and related systems and methods
CN108712911A (zh) 2015-12-30 2018-10-26 科达制药股份有限公司 抗体及其缀合物
EP4049683A1 (de) 2016-04-29 2022-08-31 Adverum Biotechnologies, Inc. Evasion von neutralisierenden antikörpern durch ein rekombinantes adeno-assoziiertes virus
RS63282B1 (sr) 2016-06-16 2022-06-30 Adverum Biotechnologies Inc Kompozicije i postupci za smanjenje očne neovaskularizacije
WO2018075798A1 (en) 2016-10-19 2018-04-26 Adverum Biotechnologies, Inc. Modified aav capsids and uses thereof
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
AU2018234918B2 (en) 2017-03-17 2023-11-02 Adverum Biotechnologies, Inc. Compositions and methods for enhanced gene expression
CN116059318A (zh) 2018-01-26 2023-05-05 加利福尼亚大学董事会 用于使用抗vegf剂治疗血管生成病症的方法和组合物
US20210015899A1 (en) * 2018-03-22 2021-01-21 The Children's Medical Center Corporation Methods and compositions relating to lung repair
TW202106699A (zh) 2019-04-26 2021-02-16 美商愛德維仁生物科技公司 用於玻璃體內遞送之變異體aav蛋白殼
US11912784B2 (en) 2019-10-10 2024-02-27 Kodiak Sciences Inc. Methods of treating an eye disorder
KR20220104756A (ko) 2019-11-25 2022-07-26 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 안구내 신생혈관형성을 위한 장기지속형 vegf 억제제
BR112023024375A2 (pt) 2021-05-28 2024-02-15 Shanghai Regenelead Therapies Co Ltd Vírus adeno-associado recombinante tendo capsídeo variante e sua aplicação
AU2022383744A1 (en) * 2021-11-02 2024-05-02 Enumita As Tri-, tetra and pentapeptides, compositions thereof and their use in the therapy of psoriasis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69232718T2 (de) * 1991-02-22 2003-04-03 American Cyanamid Co Identifizierung eines menschlichen rezeptor-tyrosinkinasegens
RO119721B1 (ro) * 1992-10-28 2005-02-28 Genentech Inc. Antagonişti ai factorului de creştere al celulelor vasculare endoteliale
CN1173991C (zh) * 1992-11-13 2004-11-03 马克斯普朗克科学促进协会 作为血管内皮生长因子受体的f1k-1

Also Published As

Publication number Publication date
DK0694042T3 (da) 2005-02-14
IL109016A (en) 2005-07-25
US20090247460A1 (en) 2009-10-01
IL109016A0 (en) 1994-06-24
US20030120038A1 (en) 2003-06-26
EP0694042A4 (de) 2001-05-02
DE69434115T2 (de) 2005-10-27
AU684498B2 (en) 1997-12-18
US5861484A (en) 1999-01-19
CA2158745C (en) 2007-06-19
JP3734262B2 (ja) 2006-01-11
PT694042E (pt) 2005-02-28
EP0694042A1 (de) 1996-01-31
US7071159B2 (en) 2006-07-04
CA2158745A1 (en) 1994-09-29
EP0694042B1 (de) 2004-11-03
WO1994021679A1 (en) 1994-09-29
ES2230542T3 (es) 2005-05-01
US5712380A (en) 1998-01-27
US8034772B2 (en) 2011-10-11
AU6393494A (en) 1994-10-11
US20070010442A1 (en) 2007-01-11
JPH08508161A (ja) 1996-09-03
ATE281469T1 (de) 2004-11-15

Similar Documents

Publication Publication Date Title
DE69434115D1 (de) Inhibitor des wachstumsfaktors für gefäss-endothelzellen
DE69918946D1 (de) Rezeptoren für il-18
DK1482042T3 (da) Aktive og inaktive CC-kemokinreceptorer og nukleinsyremolekyler der koder for receptoren
DK0930365T3 (da) Bindingsdomæner i Serrate-protein
DE69637890D1 (de) Monoklonaler antikörper für die inhibierung von hiv-1-hüllgykoprotein-vermittelte membranfusion
DK0726952T3 (da) Receptor benævnt ACT-4 på overfladen af aktiverede T-celler
BR9407377A (pt) Toxina hibrida
NO982715D0 (no) Endotel celle-proliferasjonsinhibitor og fremgangsmÕte for anvendelse
DK1129186T3 (da) Et faktor VIII-polypeptid med faktor VIII:C-aktivitet
NO960939D0 (no) Kininogenaseinhibitor
GR3031607T3 (en) Selective system scan for multizone radiotelephone subscriber units.
ATE466020T1 (de) Neue isoform des gefässendothelzell wachstumshemmers (vegi)
GR3029483T3 (en) Antibodies against t-cells as therapeutics
ATE288280T1 (de) Verfahren zum blokieren von sec-rezeptoren
GB2342652A (en) Polypeptides comprising a coiled-coil and an addition
ATE394419T1 (de) Peptidantagonisten von dp transkriptionsfaktoren
AU2434400A (en) Method for the cellular high-throughput-detection of nuclear receptor ligand interactions
ATE217088T1 (de) Bestimmung der endständigen sialinsäurereste des human-transferrin-moleküls
DK0583352T3 (da) hGPIIB fragmenter og deres anvendelse i in vitro metoder til bestemmelse af in vivo thrombotiske tilstande
WO1996023883A3 (en) Modified ligands for receptor tyrosine kinases
DE69205005D1 (de) Verwendung von Atelokollagen als Festträger für die Fixierung eines spezifischen Fängers.
DK0889907T3 (da) Monoklonale antistoffer, som binder humant væksthormon (hGH)
Ogilvie Antibodies and peptides as probes of platelet functions.
Nebigil Characterization and second messenger systems of alpha adrenergic receptor subtypes involved in prostaglandin production in vascular smooth muscle cells of rabbit aorta.
EP0367554A3 (de) Insulinbindende Wirkstoffe und Hemmer der Insulinbindung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee